Streetbeat News

TRYPF

Tryp Therapeutics Inc

Industry

Medicinal and Botanical Manufacturing

Open

0.04

Mkt cap

5.4M

Volume

31K

High

0.06

P/E Ratio

-1.87

52-wk high

0.09

Low

0.03

Div yield

N/A

52-wk low

0.00

Tryp Therapeutics Inc. (OTCQB:TRYPF) has received approval from Exopharm Limited shareholders for a merger, creating Tryptamine Therapeutics Limited. The merger, valued at CA$12.8 million, offers Tryp shareholders a significant premium, with Exopharm issuing 4.52 shares for each Tryp share. Trading of Tryp shares will halt on April 29, 2024, ahead of the ASX listing under ticker 'TYP' by mid-May 2024. This strategic move aims to enhance shareholder value and expand clinical programs, leveraging Australia's biotech landscape.

Portfolio Pulse from Patricio Liddle

April 25, 2024 | 3:05 pm

MAPS Public Benefit Corporation, a subsidiary of MAPS, has raised over $100M in Series A funding to support FDA approval of MDMA for PTSD treatment. The U.S. Department of Veterans Affairs is funding psychedelic research for veterans with PTSD and depression. A list of 30 influential figures in psychedelics for 2024 was highlighted. Psychedelics policy reform is advancing in 13 states. Psychedelics stocks and ETFs showed varied performance, with some like GH Research and Atai Life Sciences closing higher, while others like Clearmind Medicine saw a decline.

Portfolio Pulse from Lara Goldstein

January 12, 2024 | 9:55 pm

The House Rules Committee blocked all drug policy amendments to the National Defense Authorization Act (NDAA), preventing them from advancing to a floor vote. The American Psychedelic Practitioners Association (APPA) is working to legitimize the field of psychedelics. Bright Minds (NASDAQ:DRUG) consolidated its shares 5:1 to remain Nasdaq-listed, Lucy Scientific (NASDAQ:LSDI) appointed a new CEO, Tryp Therapeutics (OTC:TRYPF) received FDA approval for its Phase 2 psilocybin trial, and AdvisorShares Psychedelics ETF (NYSE:PSIL) maintained its opening price from the previous week.

Portfolio Pulse from Lara Goldstein

July 19, 2023 | 10:43 pm

Tryp Therapeutics' (OTCQB:TRYPF) Investigational New Drug (IND) application has been approved by the FDA, allowing the company to begin Phase 2a clinical trials at Massachusetts General Hospital on the effects of psilocybin-assisted psychotherapy for adults with Irritable Bowel Syndrome (IBS). The company's lead psilocin compound TRP-8803 is currently being assessed in a Phase 2a trial for the treatment of binge eating disorder. Its synthetic oral psilocybin, TRP-8802, will be studied in a Phase 2a trial for the treatment of fibromyalgia and IBS.

Portfolio Pulse from Lara Goldstein

July 13, 2023 | 7:48 pm

Silo Pharma (NASDAQ:SILO) has entered into an R&D agreement to study and develop a dosage and time-release ketamine implant for fibromyalgia and chronic pain. The project includes analytical testing and preclinical proof-of-concept trials. Silo's existing R&D program includes novel compound SP-26, a time-released, dosage-controlled ketamine formulation.

Portfolio Pulse from Lara Goldstein

June 13, 2023 | 6:05 pm

Tryp Therapeutics has submitted an Investigational New Drug application to the FDA for a phase 2a clinical trial of psilocybin-assisted psychotherapy in treating patients with irritable bowel syndrome (IBS) at Massachusetts General Hospital. The study will be conducted in collaboration with Harvard Medical School/Massachusetts General Hospital.

Portfolio Pulse from Vuk Zdinjak

May 24, 2023 | 3:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.